6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
incidence	VB	incidence	incidence	incid	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
were	VBD	were	were	were	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O
report	VB	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Eisai	NNP	eisai	eisai	eisai	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
877	CD	877	877	877	N	O
-	:	-	-	-	N	O
873	CD	873	873	873	N	O
-	:	-	-	-	N	O
4724	CD	4724	4724	4724	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
contact	JJ	contact	contact	contact	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	NN	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trials	NNS	trials	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

QT	NNP	qt	qt	qt	N	B-AdverseReaction
interval	JJ	interval	interval	interv	N	I-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
25%	CD	25%	25%	25%	N	O
)	)	)	)	)	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
were	VBD	were	were	were	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
were	VBD	were	were	were	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
neutropenia	$	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
was	VBD	was	wa	wa	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O

clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
222	CD	222	222	222	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
multiple	JJ	multiple	multiple	multipl	N	O
tumor	NN	tumor	tumor	tumor	N	O
types	NNS	types	type	type	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
240	CD	240	240	240	N	O
patients	NNS	patients	patient	patient	N	O
exposed	VBN	exposed	exposed	expos	N	O
to	TO	to	to	to	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
for	IN	for	for	for	N	O
6	CD	6	6	6	N	O
months	NNS	months	month	month	N	O
or	CC	or	or	or	N	O
longer	JJR	longer	longer	longer	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
222	CD	222	222	222	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
women	NNS	women	woman	women	N	O
(	(	(	(	(	N	O
82%	CD	82%	82%	82%	N	O
)	)	)	)	)	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
age	NN	age	age	age	N	O
of	IN	of	of	of	N	O
58	CD	58	58	58	N	O
years	NNS	years	year	year	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
:	:	:	:	:	N	O
26	CD	26	26	26	N	O
to	TO	to	to	to	N	O
91	CD	91	91	91	N	O
years	NNS	years	year	year	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
racial	JJ	racial	racial	racial	N	O
and	CC	and	and	and	N	O
ethnic	JJ	ethnic	ethnic	ethnic	N	O
distribution	NN	distribution	distribution	distribut	N	O
was	VBD	was	wa	wa	N	O
Caucasian	NNP	caucasian	caucasian	caucasian	N	O
(	(	(	(	(	N	O
83%	CD	83%	83%	83%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Black	NNP	black	black	black	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Asian	NNP	asian	asian	asian	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
other	JJ	other	other	other	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
described	VBN	described	described	describ	N	O
in	IN	in	in	in	N	O
Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
were	VBD	were	were	were	N	O
identified	VBN	identified	identified	identifi	N	O
in	IN	in	in	in	N	O
750	CD	750	750	750	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Clinical	JJ	clinical	clinical	clinic	N	O
Studies	NNP	studies	study	studi	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
randomized	VBN	randomized	randomized	random	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
to	TO	to	to	to	N	O
receive	VB	receive	receive	receiv	N	O
either	RB	either	either	either	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
(	(	(	(	(	N	O
1.4	CD	1.4	1.4	1.4	N	O
mg	NN	mg	mg	mg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
on	IN	on	on	on	N	O
Days	NNS	days	day	day	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
8	CD	8	8	8	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
21	CD	21	21	21	N	O
-	:	-	-	-	N	O
day	NN	day	day	day	N	O
cycle	NN	cycle	cycle	cycl	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
single	JJ	single	single	singl	N	O
agent	NN	agent	agent	agent	N	O
treatment	NN	treatment	treatment	treatment	N	O
chosen	VBN	chosen	chosen	chosen	N	O
by	IN	by	by	by	N	O
their	PRP$	their	their	their	N	O
physician	NN	physician	physician	physician	N	O
(	(	(	(	(	N	O
control	VB	control	control	control	N	O
group	NN	group	group	group	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

A	DT	a	a	a	N	O
total	NN	total	total	total	N	O
of	IN	of	of	of	N	O
503	CD	503	503	503	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
247	CD	247	247	247	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
group	NN	group	group	group	N	O
received	VBD	received	received	receiv	N	O
therapy	JJ	therapy	therapy	therapi	N	O
consisting	NN	consisting	consisting	consist	N	O
of	IN	of	of	of	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
[	NNP	[	[	[	N	O
total	JJ	total	total	total	N	O
97%	CD	97%	97%	97%	N	O
(	(	(	(	(	N	O
anthracyclines	NNS	anthracyclines	anthracyclines	anthracyclin	N	O
10%	CD	10%	10%	10%	N	O
,	,	,	,	,	N	O
capecitabine	NN	capecitabine	capecitabine	capecitabin	N	O
18%	CD	18%	18%	18%	N	O
,	,	,	,	,	N	O
gemcitabine	NN	gemcitabine	gemcitabine	gemcitabin	N	O
19%	CD	19%	19%	19%	N	O
,	,	,	,	,	N	O
taxanes	NNS	taxanes	taxanes	taxan	N	O
15%	CD	15%	15%	15%	N	O
,	,	,	,	,	N	O
vinorelbine	NN	vinorelbine	vinorelbine	vinorelbin	N	O
25%	CD	25%	25%	25%	N	O
,	,	,	,	,	N	O
other	JJ	other	other	other	N	O
chemotherapies	NNS	chemotherapies	chemotherapy	chemotherapi	N	O
10%	CD	10%	10%	10%	N	O
)]	NN	)]	)]	)]	N	O
or	CC	or	or	or	N	O
hormonal	JJ	hormonal	hormonal	hormon	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
exposure	NN	exposure	exposure	exposur	N	O
was	VBD	was	wa	wa	N	O
118	CD	118	118	118	N	O
days	NNS	days	day	day	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
and	CC	and	and	and	N	O
63	CD	63	63	63	N	O
days	NNS	days	day	day	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
control	NN	control	control	control	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
reports	NNS	reports	report	report	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurring	VBG	occurring	occurring	occur	N	O
in	IN	in	in	in	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
either	DT	either	either	either	N	O
group	NN	group	group	group	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNS	reactions	reaction	reaction	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
Per	NNP	per	per	per	N	O
-	:	-	-	-	N	O
Patient	JJ	patient	patient	patient	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
at	IN	at	at	at	N	O
Least	JJS	least	least	least	N	O
10%	CD	10%	10%	10%	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

MedDRA	NNP	meddra	meddra	meddra	N	O
ver	RB	ver	ver	ver	N	O
10.0	CD	10.0	10.0	10.0	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
n	RB	n	n	n	N	O
503	CD	503	503	503	N	O
Control	NNP	control	control	control	N	O
Group	NNP	group	group	group	N	O
n	VBD	n	n	n	N	O
247	CD	247	247	247	N	O

All	DT	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
All	NNP	all	all	all	N	O
Grades	NNP	grades	grade	grade	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	NNP	lymphatic	lymphatic	lymphat	N	O
System	NNP	system	system	system	N	O
Disorders	VBZ	disorders	disorder	disord	N	O
a	DT	a	a	a	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
82%	CD	82%	82%	82%	N	O
57%	CD	57%	57%	57%	N	O
53%	CD	53%	53%	53%	N	O
23%	CD	23%	23%	23%	N	O

Anemia	NNP	anemia	anemia	anemia	Y	B-AdverseReaction
58%	CD	58%	58%	58%	N	O
2%	CD	2%	2%	2%	N	O
55%	CD	55%	55%	55%	N	O
4%	CD	4%	4%	4%	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
system	NN	system	system	system	N	O
disorders	NNS	disorders	disorder	disord	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
b	VBD	b	b	b	N	O
35%	CD	35%	35%	35%	N	O
8%	CD	8%	8%	8%	N	O
16%	CD	16%	16%	16%	N	O
2%	CD	2%	2%	2%	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
19%	CD	19%	19%	19%	N	O
1%	CD	1%	1%	1%	N	O
12%	CD	12%	12%	12%	N	O
1%	CD	1%	1%	1%	N	O

General	NNP	general	general	gener	N	O
disorders	NNS	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
administrative	JJ	administrative	administrative	administr	N	O
site	NN	site	site	site	N	O
conditions	NNS	conditions	condition	condit	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
Fatigue	NNP	fatigue	fatigue	fatigu	Y	B-AdverseReaction
54%	CD	54%	54%	54%	N	O
10%	CD	10%	10%	10%	N	O
40%	CD	40%	40%	40%	N	O
11%	CD	11%	11%	11%	N	O

Mucosal	NNP	mucosal	mucosal	mucos	N	B-AdverseReaction
inflammation	NN	inflammation	inflammation	inflamm	Y	I-AdverseReaction
9%	CD	9%	9%	9%	N	O
1%	CD	1%	1%	1%	N	O
10%	CD	10%	10%	10%	N	O
2%	CD	2%	2%	2%	N	O

Pyrexia	NNP	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
21%	CD	21%	21%	21%	N	O
1%	CD	1%	1%	1%	N	O
13%	CD	13%	13%	13%	N	O
1%	CD	1%	1%	1%	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
25%	CD	25%	25%	25%	N	O
1%	CD	1%	1%	1%	N	O
21%	CD	21%	21%	21%	N	O
1%	CD	1%	1%	1%	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
18%	CD	18%	18%	18%	N	O
0	CD	0	0	0	N	O
18%	CD	18%	18%	18%	N	O
0	CD	0	0	0	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
35%	CD	35%	35%	35%	N	O
1%	CD	1%	1%	1%	N	O
28%	CD	28%	28%	28%	N	O
3%	CD	3%	3%	3%	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
18%	CD	18%	18%	18%	N	O
1%	CD	1%	1%	1%	N	O
18%	CD	18%	18%	18%	N	O
1%	CD	1%	1%	1%	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
connective	JJ	connective	connective	connect	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
Myalgia	NNP	myalgia	myalgia	myalgia	Y	B-AdverseReaction
22%	CD	22%	22%	22%	N	O
1%	CD	1%	1%	1%	N	O
12%	CD	12%	12%	12%	N	O
1%	CD	1%	1%	1%	N	O

Back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
16%	CD	16%	16%	16%	N	O
1%	CD	1%	1%	1%	N	O
7%	CD	7%	7%	7%	N	O
2%	CD	2%	2%	2%	N	O

Bone	NNP	bone	bone	bone	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
12%	CD	12%	12%	12%	N	O
2%	CD	2%	2%	2%	N	O
9%	CD	9%	9%	9%	N	O
2%	CD	2%	2%	2%	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
extremity	NN	extremity	extremity	extrem	N	I-AdverseReaction
11%	CD	11%	11%	11%	N	O
1%	CD	1%	1%	1%	N	O
10%	CD	10%	10%	10%	N	O
1%	CD	1%	1%	1%	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
21%	CD	21%	21%	21%	N	O
1%	CD	1%	1%	1%	N	O
14%	CD	14%	14%	14%	N	O
1%	CD	1%	1%	1%	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
nutrition	NN	nutrition	nutrition	nutrit	N	O
disorders	NNS	disorders	disorder	disord	N	O

Anorexia	NNP	anorexia	anorexia	anorexia	Y	B-AdverseReaction
20%	CD	20%	20%	20%	N	O
1%	CD	1%	1%	1%	N	O
13%	CD	13%	13%	13%	N	O
1%	CD	1%	1%	1%	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O

Cough	NNP	cough	cough	cough	Y	B-AdverseReaction
14%	CD	14%	14%	14%	N	O
0	CD	0	0	0	N	O
9%	CD	9%	9%	9%	N	O
0	CD	0	0	0	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
16%	CD	16%	16%	16%	N	O
4%	CD	4%	4%	4%	N	O
13%	CD	13%	13%	13%	N	O
4%	CD	4%	4%	4%	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
subcutaneous	JJ	subcutaneous	subcutaneous	subcutan	N	O
tissue	NN	tissue	tissue	tissu	N	O
disorders	NNS	disorders	disorder	disord	N	O

Alopecia	$	alopecia	alopecia	alopecia	Y	B-AdverseReaction
45%	CD	45%	45%	45%	N	O
NA	NNP	na	na	na	N	O
c	VBD	c	c	c	N	O
10%	CD	10%	10%	10%	N	O
NA	NNP	na	na	na	N	O
c	NN	c	c	c	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infection	NNP	infection	infection	infect	Y	I-AdverseReaction
10%	CD	10%	10%	10%	N	O
1%	CD	1%	1%	1%	N	O
5%	CD	5%	5%	5%	N	O
0	CD	0	0	0	N	O

a	DT	a	a	a	N	O
.	.	.	.	.	N	O
based	VBN	based	based	base	N	O
upon	IN	upon	upon	upon	N	O
laboratory	NN	laboratory	laboratory	laboratori	N	O
data	NNS	data	data	data	N	O
.	.	.	.	.	N	O

b	NN	b	b	b	N	O
includes	VBZ	includes	includes	includ	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
peripheral	NN	peripheral	peripheral	peripher	N	I-AdverseReaction
,	,	,	,	,	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
polyneuropathy	NN	polyneuropathy	polyneuropathy	polyneuropathi	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
sensoryneuropathy	NN	sensoryneuropathy	sensoryneuropathy	sensoryneuropathi	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
paraesthesia	NN	paraesthesia	paraesthesia	paraesthesia	Y	B-AdverseReaction
.	.	.	.	.	N	O

c	NNS	c	c	c	N	O
not	RB	not	not	not	N	O
applicable	JJ	applicable	applicable	applic	N	O
;	:	;	;	;	N	O
(	(	(	(	(	N	O
grading	VBG	grading	grading	grade	N	O
system	NN	system	system	system	N	O
does	VBZ	does	doe	doe	N	O
not	RB	not	not	not	N	O
specify	VB	specify	specify	specifi	N	O
Grade	NNP	grade	grade	grade	N	O
2	CD	2	2	2	N	O
for	IN	for	for	for	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Cytopenias	NNS	cytopenias	cytopenia	cytopenia	N	O
:	:	:	:	:	N	O
Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
28%	CD	28%	28%	28%	N	O
(	(	(	(	(	N	O
143	CD	143	143	143	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
29%	CD	29%	29%	29%	N	O
(	(	(	(	(	N	O
144	CD	144	144	144	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experienced	JJ	experienced	experienced	experienc	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Febrile	NNP	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
23	CD	23	23	23	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
;	:	;	;	;	N	O
two	CD	two	two	two	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
)	)	)	)	)	N	O
died	VBD	died	died	die	N	B-AdverseReaction
from	IN	from	from	from	N	O
complications	NNS	complications	complication	complic	N	O
of	IN	of	of	of	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
neutropenia	DT	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
required	VBN	required	required	requir	N	O
in	IN	in	in	in	N	O
12%	CD	12%	12%	12%	N	O
(	(	(	(	(	N	O
62	CD	62	62	62	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
was	VBD	was	wa	wa	N	O
required	VBN	required	required	requir	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
nadir	VB	nadir	nadir	nadir	N	O
was	VBD	was	wa	wa	N	O
13	CD	13	13	13	N	O
days	NNS	days	day	day	N	O
and	CC	and	and	and	N	O
the	DT	the	the	the	N	O
mean	JJ	mean	mean	mean	N	O
time	NN	time	time	time	N	O
to	TO	to	to	to	N	O
recovery	NN	recovery	recovery	recoveri	N	O
from	IN	from	from	from	N	O
severe	JJ	severe	severe	sever	N	B-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
500	CD	500	500	500	N	O
mm	RB	mm	mm	mm	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
8	CD	8	8	8	N	O
days	NNS	days	day	day	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
(	(	(	(	(	N	O
7	CD	7	7	7	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

G	NNP	g	g	g	N	O
-	:	-	-	-	N	O
CSF	NNP	csf	csf	csf	N	O
(	(	(	(	(	N	O
granulocyte	NN	granulocyte	granulocyte	granulocyt	N	O
colony	NN	colony	colony	coloni	N	O
-	:	-	-	-	N	O
stimulating	JJ	stimulating	stimulating	stimul	N	O
factor	NN	factor	factor	factor	N	O
)	)	)	)	)	N	O
or	CC	or	or	or	N	O
GM	NNP	gm	gm	gm	N	O
-	:	-	-	-	N	O
CSF	NNP	csf	csf	csf	N	O
(	(	(	(	(	N	O
granulocyte	JJ	granulocyte	granulocyte	granulocyt	N	O
-	:	-	-	-	N	O
macrophage	NN	macrophage	macrophage	macrophag	N	O
colony	NN	colony	colony	coloni	N	O
-	:	-	-	-	N	O
stimulating	JJ	stimulating	stimulating	stimul	N	O
factor	NN	factor	factor	factor	N	O
)	)	)	)	)	N	O
was	VBD	was	wa	wa	N	O
used	VBN	used	used	use	N	O
in	IN	in	in	in	N	O
19%	CD	19%	19%	19%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
.	.	.	.	.	N	O

Peripheral	JJ	peripheral	peripheral	peripher	N	O

Neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O
:	:	:	:	:	N	O
In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
17	CD	17	17	17	N	O
of	IN	of	of	of	N	O
enrolled	JJ	enrolled	enrolled	enrol	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
Grade	VBN	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NNS	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
and	CC	and	and	and	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
had	VBD	had	had	had	N	O
Grade	VBN	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
reduction	NN	reduction	reduction	reduct	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
required	VBN	required	required	requir	N	O
by	IN	by	by	by	N	O
3%	CD	3%	3%	3%	N	O
(	(	(	(	(	N	O
14	CD	14	14	14	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
.	.	.	.	.	N	O

Four	CD	four	four	four	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
20	CD	20	20	20	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
experienced	JJ	experienced	experienced	experienc	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
(	(	(	(	(	N	O
8	CD	8	8	8	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBN	developed	developed	develop	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
motor	NN	motor	motor	motor	N	I-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
.	.	.	.	.	N	O

Liver	NNP	liver	liver	liver	N	O
Function	NNP	function	function	function	N	O
Test	NNP	test	test	test	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
:	:	:	:	:	N	O
Among	IN	among	among	among	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Grade	NNP	grade	grade	grade	N	O
0	CD	0	0	0	N	O
or	CC	or	or	or	N	O
1	CD	1	1	1	N	O
ALT	JJ	alt	alt	alt	N	O
levels	NNS	levels	level	level	N	O
at	IN	at	at	at	N	O
baseline	NN	baseline	baseline	baselin	N	O
,	,	,	,	,	N	O
18%	CD	18%	18%	18%	N	O
of	IN	of	of	of	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
ALT	NNP	alt	alt	alt	N	B-AdverseReaction
elevation	NN	elevation	elevation	elev	N	I-AdverseReaction
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patient	NN	patient	patient	patient	N	O
without	IN	without	without	without	N	O
documented	VBN	documented	documented	document	N	O
liver	NN	liver	liver	liver	N	O
metastases	NNS	metastases	metastasis	metastas	N	O
had	VBD	had	had	had	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
and	CC	and	and	and	N	O
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
;	:	;	;	;	N	O
these	DT	these	these	these	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
resolved	VBD	resolved	resolved	resolv	N	O
and	CC	and	and	and	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
recur	VB	recur	recur	recur	N	O
with	IN	with	with	with	N	O
re	JJ	re	re	re	N	O
-	:	-	-	-	N	O
exposure	NN	exposure	exposure	exposur	N	O
to	TO	to	to	to	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
.	.	.	.	.	N	O

Less	NNP	less	le	less	N	O
Common	NNP	common	common	common	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
additional	JJ	additional	additional	addit	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
to	TO	to	to	to	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
-	:	-	-	-	N	O
treated	VBN	treated	treated	treat	N	O
group	NN	group	group	group	N	O
:	:	:	:	:	N	O

Eye	JJ	eye	eye	eye	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
increased	VBN	increased	increased	increas	N	B-AdverseReaction
lacrimation	NN	lacrimation	lacrimation	lacrim	Y	I-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
dyspepsia	NN	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
stomatitis	NN	stomatitis	stomatitis	stomat	Y	B-AdverseReaction
,	,	,	,	,	N	O
dry	JJ	dry	dry	dri	N	B-AdverseReaction
mouth	NN	mouth	mouth	mouth	N	I-AdverseReaction

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O
:	:	:	:	:	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	B-AdverseReaction

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
muscle	NN	muscle	muscle	muscl	N	B-AdverseReaction
spasms	NNS	spasms	spasm	spasm	Y	I-AdverseReaction
,	,	,	,	,	N	O
muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
weakness	NN	weakness	weakness	weak	Y	I-AdverseReaction

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NN	system	system	system	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
insomnia	NN	insomnia	insomnia	insomnia	Y	B-AdverseReaction
,	,	,	,	,	N	O
depression	NN	depression	depression	depress	Y	B-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
rash	NN	rash	rash	rash	Y	B-AdverseReaction

6	CD	6	6	6	N	O
.	.	.	.	.	N	O

2	CD	2	2	2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
during	IN	during	during	dure	N	O
post	NN	post	post	post	N	O
-	:	-	-	-	N	O
approval	NN	approval	approval	approv	N	O
of	IN	of	of	of	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
voluntarily	RB	voluntarily	voluntarily	voluntarili	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
uncertain	JJ	uncertain	uncertain	uncertain	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
always	RB	always	always	alway	N	O
possible	JJ	possible	possible	possibl	N	O
to	TO	to	to	to	N	O
reliably	VB	reliably	reliably	reliabl	N	O
estimate	VB	estimate	estimate	estim	N	O
their	PRP$	their	their	their	N	O
frequency	NN	frequency	frequency	frequenc	N	O
or	CC	or	or	or	N	O
establish	VB	establish	establish	establish	N	O
a	DT	a	a	a	N	O
causal	NN	causal	causal	causal	N	O
relationship	NN	relationship	relationship	relationship	N	O
to	TO	to	to	to	N	O
drug	NN	drug	drug	drug	N	O
exposure	NN	exposure	exposure	exposur	N	O
.	.	.	.	.	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	NNP	lymphatic	lymphatic	lymphat	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
lymphopenia	NN	lymphopenia	lymphopenia	lymphopenia	Y	B-AdverseReaction

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
pancreatitis	NN	pancreatitis	pancreatitis	pancreat	Y	B-AdverseReaction

Hepatobiliary	JJ	hepatobiliary	hepatobiliary	hepatobiliari	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hepatotoxicity	NN	hepatotoxicity	hepatotoxicity	hepatotox	Y	B-AdverseReaction

Immune	NNP	immune	immune	immun	N	O
System	NNP	system	system	system	N	O
Disorders	NNPS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
drug	NN	drug	drug	drug	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O
:	:	:	:	:	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
neutropenic	JJ	neutropenic	neutropenic	neutropen	N	B-AdverseReaction
sepsis	NN	sepsis	sepsis	sepsi	Y	I-AdverseReaction

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
thoracic	NN	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
mediastinal	JJ	mediastinal	mediastinal	mediastin	N	O
disorders	NNS	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
interstitial	JJ	interstitial	interstitial	interstiti	N	B-AdverseReaction
lung	NN	lung	lung	lung	N	I-AdverseReaction
disease	NN	disease	disease	diseas	N	I-AdverseReaction

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O
:	:	:	:	:	N	O
pruritus	NN	pruritus	pruritus	pruritu	Y	B-AdverseReaction
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
counts	NNS	counts	count	count	N	O
and	CC	and	and	and	N	O
adjust	VBP	adjust	adjust	adjust	N	O
dose	VB	dose	dose	dose	N	O
as	IN	as	a	as	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.1	CD	5.1	5.1	5.1	N	O
,	,	,	,	,	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
Neuropathy	NNP	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O
.	.	.	.	.	N	O

Manage	NN	manage	manage	manag	N	O
with	IN	with	with	with	N	O
dose	JJ	dose	dose	dose	N	O
delay	NN	delay	delay	delay	N	O
and	CC	and	and	and	N	O
adjustment	NN	adjustment	adjustment	adjust	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
,	,	,	,	,	N	O
5.2	CD	5.2	5.2	5.2	N	O
,	,	,	,	,	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

Embryo	NNP	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
Toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
:	:	:	:	:	N	O
Fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O

QT	JJ	qt	qt	qt	N	B-AdverseReaction
Prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
:	:	:	:	:	N	O
Monitor	NN	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
prolonged	JJ	prolonged	prolonged	prolong	N	O
QT	NNP	qt	qt	qt	N	O
intervals	NNS	intervals	interval	interv	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
congestive	JJ	congestive	congestive	congest	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
bradyarrhythmias	NN	bradyarrhythmias	bradyarrhythmias	bradyarrhythmia	N	O
,	,	,	,	,	N	O
drugs	NNS	drugs	drug	drug	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
prolong	VB	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
electrolyte	JJ	electrolyte	electrolyte	electrolyt	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
congenital	JJ	congenital	congenital	congenit	N	O
long	JJ	long	long	long	N	O
QT	NNP	qt	qt	qt	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O

Severe	JJ	severe	severe	sever	N	B-Severity

neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
ANC	NNP	anc	anc	anc	N	O
500	CD	500	500	500	N	O
mm	$	mm	mm	mm	N	O
3	CD	3	3	3	N	O
)	)	)	)	)	N	O
lasting	VBG	lasting	lasting	last	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
week	NN	week	week	week	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
12%	CD	12%	12%	12%	N	O
(	(	(	(	(	N	O
62	CD	62	62	62	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
[	JJ	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
alanine	JJ	alanine	alanine	alanin	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
or	CC	or	or	or	N	O
aspartate	VB	aspartate	aspartate	aspart	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
3	CD	3	3	3	N	O
ULN	NNP	uln	uln	uln	N	O
(	(	(	(	(	N	O
upper	JJ	upper	upper	upper	N	O
limit	NN	limit	limit	limit	N	O
of	IN	of	of	of	N	O
normal	JJ	normal	normal	normal	N	O
)	)	)	)	)	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
febrile	NN	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
than	IN	than	than	than	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
normal	JJ	normal	normal	normal	N	O
aminotransferase	NN	aminotransferase	aminotransferase	aminotransferas	N	O
levels	NNS	levels	level	level	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
bilirubin	JJ	bilirubin	bilirubin	bilirubin	Y	O
1.5	CD	1.5	1.5	1.5	N	O
ULN	NNP	uln	uln	uln	N	O
also	RB	also	also	also	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
higher	JJR	higher	higher	higher	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
each	DT	each	each	each	N	O
dose	NN	dose	dose	dose	N	O
;	:	;	;	;	N	O
increase	VB	increase	increase	increas	N	O
the	DT	the	the	the	N	O
frequency	NN	frequency	frequency	frequenc	N	O
of	IN	of	of	of	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
cytopenias	NNS	cytopenias	cytopenia	cytopenia	N	O
.	.	.	.	.	N	O

Delay	NNP	delay	delay	delay	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
and	CC	and	and	and	N	O
reduce	VB	reduce	reduce	reduc	N	O
subsequent	JJ	subsequent	subsequent	subsequ	N	O
doses	NNS	doses	dos	dose	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experience	VBP	experience	experience	experi	N	O
febrile	JJ	febrile	febrile	febril	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
or	CC	or	or	or	N	O
Grade	VB	grade	grade	grade	N	O
4	CD	4	4	4	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	O
lasting	NN	lasting	lasting	last	N	O
longer	JJR	longer	longer	longer	N	O
than	IN	than	than	than	N	O
7	CD	7	7	7	N	O
days	NNS	days	day	day	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
include	VB	include	include	includ	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
baseline	JJ	baseline	baseline	baselin	N	O
neutrophil	NN	neutrophil	neutrophil	neutrophil	N	O
counts	NNS	counts	count	count	N	O
below	IN	below	below	below	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
500	CD	500	500	500	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Peripheral	NNP	peripheral	peripheral	peripher	N	O
Neuropathy	NNP	neuropathy	neuropathy	neuropathi	Y	O

Grade	$	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	RB	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
8%	CD	8%	8%	8%	N	O
(	(	(	(	(	N	O
40	CD	40	40	40	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
in	IN	in	in	in	N	O
0.4%	CD	0.4%	0.4%	0.4%	N	O
(	(	(	(	(	N	O
2	CD	2	2	2	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
was	VBD	was	wa	wa	N	O
the	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
;	:	;	;	;	N	O
24	CD	24	24	24	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
lasting	VBG	lasting	lasting	last	N	O
more	JJR	more	more	more	N	O
than	IN	than	than	than	N	O
one	CD	one	one	one	N	O
year	NN	year	year	year	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
(	(	(	(	(	N	O
26	CD	26	26	26	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Twenty	CD	twenty	twenty	twenti	N	O
-	:	-	-	-	N	O
two	CD	two	two	two	N	O
percent	NN	percent	percent	percent	N	O
(	(	(	(	(	N	O
109	CD	109	109	109	N	O
503	CD	503	503	503	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
developed	VBD	developed	developed	develop	N	O
a	DT	a	a	a	N	O
new	JJ	new	new	new	N	O
or	CC	or	or	or	N	O
worsening	VBG	worsening	worsening	worsen	N	O
neuropathy	JJ	neuropathy	neuropathy	neuropathi	Y	B-AdverseReaction
that	WDT	that	that	that	N	O
had	VBD	had	had	had	N	O
not	RB	not	not	not	N	O
recovered	VBN	recovered	recovered	recov	N	O
within	IN	within	within	within	N	O
a	DT	a	a	a	N	O
median	JJ	median	median	median	N	O
follow	NN	follow	follow	follow	N	O
-	:	-	-	-	N	O
up	IN	up	up	up	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
269	CD	269	269	269	N	O
days	NNS	days	day	day	N	O
(	(	(	(	(	N	O
range	NN	range	range	rang	N	O
25	CD	25	25	25	N	O
-	:	-	-	-	N	O
662	CD	662	662	662	N	O
days	NNS	days	day	day	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Monitor	NN	monitor	monitor	monitor	N	O
patients	NNS	patients	patient	patient	N	O
closely	RB	closely	closely	close	N	O
for	IN	for	for	for	N	O
signs	NNS	signs	sign	sign	N	O
of	IN	of	of	of	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	O
motor	NN	motor	motor	motor	N	O
and	CC	and	and	and	N	O
sensory	JJ	sensory	sensory	sensori	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O
.	.	.	.	.	N	O

Withhold	NNP	withhold	withhold	withhold	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experience	VBP	experience	experience	experi	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
or	CC	or	or	or	N	O
4	CD	4	4	4	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	O
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	O
until	IN	until	until	until	N	O
resolution	NN	resolution	resolution	resolut	N	O
to	TO	to	to	to	N	O
Grade	VB	grade	grade	grade	N	O
2	CD	2	2	2	N	O
or	CC	or	or	or	N	O
less	JJR	less	le	less	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Embryo	NNP	embryo	embryo	embryo	N	O
-	:	-	-	-	N	O
Fetal	JJ	fetal	fetal	fetal	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
no	DT	no	no	no	N	O
adequate	JJ	adequate	adequate	adequ	N	O
and	CC	and	and	and	N	O
well	RB	well	well	well	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
of	IN	of	of	of	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
in	IN	in	in	in	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
women	NNS	women	woman	women	N	O
.	.	.	.	.	N	O

HALAVEN	NNP	halaven	halaven	halaven	N	O
is	VBZ	is	is	is	N	O
a	DT	a	a	a	N	O
microtubule	NN	microtubule	microtubule	microtubul	N	B-DrugClass
inhibitor	NN	inhibitor	inhibitor	inhibitor	N	I-DrugClass
;	:	;	;	;	N	O
therefore	RB	therefore	therefore	therefor	N	O
,	,	,	,	,	N	O
it	PRP	it	it	it	N	O
is	VBZ	is	is	is	N	O
expected	VBN	expected	expected	expect	N	O
to	TO	to	to	to	N	O
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

Embryo	NNP	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
toxicity	NN	toxicity	toxicity	toxic	N	I-AdverseReaction
and	CC	and	and	and	N	O
teratogenicity	NN	teratogenicity	teratogenicity	teratogen	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
rats	NNS	rats	rat	rat	N	B-Animal
that	WDT	that	that	that	N	O
received	VBD	received	received	receiv	N	O
eribulin	JJ	eribulin	eribulin	eribulin	N	O
mesylate	NN	mesylate	mesylate	mesyl	N	O
at	IN	at	at	at	N	O
approximately	RB	approximately	approximately	approxim	N	O
half	NN	half	half	half	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
human	NN	human	human	human	N	O
dose	NN	dose	dose	dose	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
body	NN	body	body	bodi	N	O
surface	JJ	surface	surface	surfac	N	O
area	NN	area	area	area	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	B-Factor
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
a	DT	a	a	a	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
she	PRP	she	she	she	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	B-Factor
[	NNP	[	[	[	N	O
see	NN	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)]	NN	)]	)]	)]	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
QT	NNP	qt	qt	qt	N	O
Prolongation	NN	prolongation	prolongation	prolong	N	O

In	IN	in	in	in	N	O
an	DT	an	an	an	N	O
uncontrolled	JJ	uncontrolled	uncontrolled	uncontrol	N	O
open	JJ	open	open	open	N	O
-	:	-	-	-	N	O
label	NN	label	label	label	N	O
ECG	NNP	ecg	ecg	ecg	Y	O
study	NN	study	study	studi	N	O
in	IN	in	in	in	N	O
26	CD	26	26	26	N	O
patients	NNS	patients	patient	patient	N	O
,	,	,	,	,	N	O
QT	NNP	qt	qt	qt	N	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
was	VBD	was	wa	wa	N	O
observed	VBN	observed	observed	observ	N	O
on	IN	on	on	on	N	O
Day	NNP	day	day	day	N	O
8	CD	8	8	8	N	O
,	,	,	,	,	N	O
independent	JJ	independent	independent	independ	N	O
of	IN	of	of	of	N	O
eribulin	JJ	eribulin	eribulin	eribulin	N	O
concentration	NN	concentration	concentration	concentr	N	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
no	DT	no	no	no	N	B-Negation
QT	NNP	qt	qt	qt	N	B-AdverseReaction
prolongation	NN	prolongation	prolongation	prolong	N	I-AdverseReaction
observed	VBD	observed	observed	observ	N	O
on	IN	on	on	on	N	O
Day	NNP	day	day	day	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

ECG	NNP	ecg	ecg	ecg	Y	O
monitoring	NN	monitoring	monitoring	monitor	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
if	IN	if	if	if	N	O
therapy	NN	therapy	therapy	therapi	N	O
is	VBZ	is	is	is	N	O
initiated	VBN	initiated	initiated	initi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
congestive	JJ	congestive	congestive	congest	N	O
heart	NN	heart	heart	heart	N	O
failure	NN	failure	failure	failur	N	O
,	,	,	,	,	N	O
bradyarrhythmias	NN	bradyarrhythmias	bradyarrhythmias	bradyarrhythmia	N	O
,	,	,	,	,	N	O
drugs	NNS	drugs	drug	drug	N	O
known	VBN	known	known	known	N	O
to	TO	to	to	to	N	O
prolong	VB	prolong	prolong	prolong	N	O
the	DT	the	the	the	N	O
QT	NNP	qt	qt	qt	N	O
interval	NN	interval	interval	interv	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
Class	NNP	class	class	class	N	O
Ia	NNP	ia	ia	ia	N	O
and	CC	and	and	and	N	O
III	NNP	iii	iii	iii	N	O
antiarrhythmics	NNS	antiarrhythmics	antiarrhythmic	antiarrhythm	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
electrolyte	JJ	electrolyte	electrolyte	electrolyt	N	O
abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
.	.	.	.	.	N	O

Correct	JJ	correct	correct	correct	N	O
hypokalemia	NN	hypokalemia	hypokalemia	hypokalemia	Y	O
or	CC	or	or	or	N	O
hypomagnesemia	NN	hypomagnesemia	hypomagnesemia	hypomagnesemia	Y	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
initiating	VBG	initiating	initiating	initi	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
and	CC	and	and	and	N	O
monitor	VB	monitor	monitor	monitor	N	O
these	DT	these	these	these	N	O
electrolytes	NNS	electrolytes	electrolyte	electrolyt	N	O
periodically	RB	periodically	periodically	period	N	O
during	IN	during	during	dure	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Avoid	NNP	avoid	avoid	avoid	N	O
HALAVEN	NNP	halaven	halaven	halaven	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
congenital	JJ	congenital	congenital	congenit	N	O
long	JJ	long	long	long	N	O
QT	NNP	qt	qt	qt	N	O
syndrome	NN	syndrome	syndrome	syndrom	N	O
.	.	.	.	.	N	O

